Clinical Remission and Reduction of Circulating Nephritic Factors by Combining Rituximab With Belimumab in a Case of Complement Factor 3 Glomerulopathy
Mieke van Schaik,
Aiko P.J. de Vries,
Frederike J. Bemelman,
Ton J. Rabelink,
Leendert A. Trouw,
Cees van Kooten,
Yoe Kie Onno Teng
Affiliations
Mieke van Schaik
Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands
Aiko P.J. de Vries
Department of Nephrology and Leiden Transplant Center, Leiden University Medical Center, Leiden, The Netherlands
Frederike J. Bemelman
Department of Nephrology, Amsterdam University Medical Center, Amsterdam, The Netherlands
Ton J. Rabelink
Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands
Leendert A. Trouw
Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands
Cees van Kooten
Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands
Yoe Kie Onno Teng
Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands; Correspondence: Yoe Kie Onno Teng, Leiden University Medical Center, Department of Nephrology, 9600, 2300RC Leiden, The Netherlands.
